Eloxx Pharmaceuticals, Inc. (ELOX)

Market Cap	330.00 -100.0%
Revenue (ttm)	n/a
Net Income	-20.48M
EPS	-8.82
Shares Out	3.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	343
Average Volume	3,295
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	n/a
Beta	-166,470.46
RSI	47.90
Earnings Date	n/a

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of RNA-modulating drugs in the United States. The company develops ELX-02, which is in phase II clinical trial for the treatment of nonsense mutation alport syndrome; ZKN013, which is in investigation phase for the treatment of nonsense mutation recessive dystrophic and junctional epidermolysis bullosa; and ZKN013, which is in investigation phase for the treatment of nonsense mutation familial adenomatous polyposis. It also offers platform techno...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 18
• Stock Exchange: OTCMKTS
• Ticker Symbol: ELOX